Skip to content

Net Income at other companies

Pfizer logo
PfizerPFE
$2.7B-9.3%
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$330.96M+174%
PTC Therapeutics logo
PTC TherapeuticsPTCT
-$2.81M-100%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
-$78.69M-46.3%
Vericel logo
VericelVCEL
-$6.3M+44.0%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
-$120.85M-4.8%

Segments

By segment

See full
Single Reportable-$33.94M-39.2%

Other financials

Income statement

See full
Revenue--100%
Operating income-$36.8M-47.2%
Net income-$33.9M-39.2%
EPS (diluted)-$0.59-11.3%

Balance sheet

See full
Cash & equivalents$105.4M+266%
Total debt$14.8M+1,083%
Total equity$278.7M+118%
Total assets$326.3M+112%

Cash flow

See full
Operating cash flow-$29.3M-355%
CapEx$5.1M+472%
Free cash flow-$34.4M-369%

Valuation

See full
Market cap$1.71B+303%

Profitability

See full
Operating margin-778.8%-1,038pp
Net margin-736.6%-981pp
FCF margin-563.9%-954pp

Returns & leverage

See full
Return on equity-56.4%-11.3pp
Debt / equity0.1×0.0×
Current ratio8.4×+1.9×

Where this comes from

Reported directly by Capricor Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProfitLoss.

The official record: Capricor Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Capricor Therapeutics's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Capricor Therapeutics's net income?
Capricor Therapeutics (CAPR) reported net income of -$33.94M in Q1 2026.
How has Capricor Therapeutics's net income changed year-over-year?
Capricor Therapeutics's net income decreased by 39.2% year-over-year, from -$24.39M to -$33.94M.
What is the long-term trend for Capricor Therapeutics's net income?
Over 4 years (2021 to 2025), Capricor Therapeutics's net income has grown at a 51.3% compound annual growth rate (CAGR), from -$20.02M to -$105.04M.
What does net income mean?
Net income as the starting point for the indirect method operating cash flow reconciliation.